{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:58:15Z","timestamp":1793465895117,"version":"4.5.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec id=\"ab-hbr250017-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Newborn screening for familial hypercholesterolemia (FH) would dramatically increase the diagnosis of a common, potentially fatal but highly treatable genetic condition in newborns and relatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250017-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To report the results of genetic testing of residual newborn screening dried blood spots (DBS) with biomarkers suggesting high risk for FH as an initial step toward development of multitier newborn screening for FH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250017-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      A cross-sectional study design from July 2021 to July 2022 was used to test residual DBS from newborns with sample collection between 24 and 72 hours of life for total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B. Principal component analysis identified biomarker combinations that accounted for the greatest variance. Mahalanobis distance was calculated to generalize the idea of a standardized\n                      <jats:italic toggle=\"yes\">z<\/jats:italic>\n                      score of a single variable to several correlated variables; approximately 8% of samples with the greatest positive Mahalanobis distance were selected for genetic FH testing. The study included a population-based screening for newborns in Wisconsin. Study data were analyzed from July 2022 to June 2024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250017-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Newborn residual DBS were tested for total cholesterol, low-density lipoprotein cholesterol, and apolipoprotein B, with a subset tested for pathogenic variants in 8 genes associated with FH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250017-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Prevalence of pathogenic variants for FH in a population-based sample of newborn screening DBS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250017-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 59\u202f927 total newborns, DBS samples were obtained from 10\u202f004 newborns (mean [SD] age, 27.8 [5.6] hours; 5142 male [51.4%]). From 10\u202f004 specimens tested, principal component analysis demonstrated the combination of low-density lipoprotein cholesterol and apolipoprotein B accounted for the greatest variance, and 768 specimens were selected for genetic testing. A pathogenic variant for FH was found in 16 samples yielding a population-based prevalence of 1 in 625 (1.6 per 1000; 95% CI, 0.91-2.60 per 1000) newborns. Pathogenic variants were distributed throughout the entire range of Mahalanobis scores selected for genetic testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr250017-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cross-sectional study found that screening newborns for FH using first-tier biochemical testing with reflex second-tier genetic testing was feasible and, in this population, identified 1 in 625 newborns with FH. Further refinement and validation are needed before implementation in newborn screening. Routine newborn screening for FH would substantially increase diagnosis of this common, potentially fatal, yet readily treatable condition while providing opportunities for cascade screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.4047","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:34:17Z","timestamp":1761752057000},"page":"1315","source":"Crossref","is-referenced-by-count":10,"title":["Genetic Diagnosis of Familial Hypercholesterolemia in Residual Newborn Dried Blood Spots"],"prefix":"10.1001","volume":"10","author":[{"given":"Amy L.","family":"Peterson","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Cardiology, University of Wisconsin Madison School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Horner","sequence":"additional","affiliation":[{"name":"Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Lasarev","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Cardiology, University of Wisconsin Madison School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Humphries","sequence":"additional","affiliation":[{"name":"Institute for Cardiovascular Science, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Genetics and Metabolism, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Marshfield Clinic Health System, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Benoy","sequence":"additional","affiliation":[{"name":"Pediatric Specialty Clinics, University of Wisconsin Hospital and Clinics, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Tumolo","sequence":"additional","affiliation":[{"name":"Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice K.","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland"},{"name":"The Oregon State Public Health Laboratory, Oregon Health Authority, Hillsboro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqiang","family":"Shao","sequence":"additional","affiliation":[{"name":"Wisconsin State Laboratory of Hygiene, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Department of Pediatrics, Division of Genetics and Metabolism, University of Wisconsin School of Medicine and Public Health, Madison"},{"name":"Marshfield Clinic Health System, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"hbr250017r1","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 US National Health and Nutrition Examination Surveys (NHANES).","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"hbr250017r2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.atherosclerosissup.2018.04.017","article-title":"Statin initiation during childhood in patients with familial hypercholesterolemia and cardiovascular risk after 20 years of follow-up (preliminary results).","volume":"32","author":"Luirink","year":"2018","journal-title":"Atheroscler Suppl"},{"issue":"45","key":"hbr250017r3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"Suppl 5","key":"hbr250017r4","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","year":"2011","journal-title":"Pediatrics"},{"issue":"17","key":"hbr250017r5","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1001\/jama.2014.2410","article-title":"Cholesterol testing among children and adolescents during health visits.","volume":"311","author":"Vinci","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"hbr250017r6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijns8010014","article-title":"Analytical validation of familial hypercholesterolemia biomarkers in dried blood spots.","volume":"8","author":"Held","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"hbr250017r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2023.113469","article-title":"Familial hypercholesterolemia biomarker distribution in dried blood spots.","volume":"259","author":"Held","year":"2023","journal-title":"J Pediatr"},{"issue":"5","key":"hbr250017r8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"10","key":"hbr250017r9","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.gim.2022.06.010","article-title":"Universal screening for familial hypercholesterolemia in 2 populations.","volume":"24","author":"Sustar","year":"2022","journal-title":"Genet Med"},{"issue":"6","key":"hbr250017r10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.5551\/jat.62780","article-title":"Universal screening for familial hypercholesterolemia in children in Kagawa, Japan.","volume":"29","author":"Matsunaga","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"hbr250017r11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the US: insights from the CASCADE FH Registry.","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"hbr250017r12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jacl.2018.12.003","article-title":"The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study.","volume":"13","author":"Luirink","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"hbr250017r13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1001\/jamacardio.2023.5366","article-title":"Familial Hypercholesterolemia variant and cardiovascular risk in individuals with elevated cholesterol.","volume":"9","author":"Zhang","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hbr250017r14","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","article-title":"Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.","volume":"50","author":"Khera","year":"2018","journal-title":"Nat Genet"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2840229\/jamacardiology_peterson_2025_br_250017_1765206636.4665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:00:36Z","timestamp":1765382436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2840229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.4047","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}